Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by LINDSEY, N. J.
Right arrow Articles by HUGHES, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LINDSEY, N. J.
Right arrow Articles by HUGHES, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1993 British Society for Rheumatology

other

STIMULATION OF VON WILLEBRAND FACTOR ANTIGEN RELEASE BY IMMUNOGLOBULIN FROM THROMBOSIS PRONE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND THE ANTIPHOSPHOLIPID SYNDROME

N. J. LINDSEY, R. A. DAWSON, F.I. HENDERSON, M. GREAVES* and P. HUGHES

University Departments of Medicine Shefield
*Haematology, Northern General and Royal Hallomshire Hospitals Shefield

Correspondence to: Correspondence to P. Hughes

The level of von Willebrand factor angtigen (vWF) released by endothelial cells in response to IgG isolated from 18 patients with systemic lupus erythematosus (SLE), eight patients with the anti-phospholipid syndrome (APS) and 22 controls has been measured. Incubation with IgG from the combined patient group resulted in a significantly greater release of vWF (mean stimulation index ± SEM, 4.57 ± 0.78) when compared with controls (1.96 ± 0.22, P = 0.003).Furthermore, IgG from 17 patients who had had a history of thrombosis induced higher levels of vWF release (5.33 ± 1.09) when compared with the controls (P = 0.008). These findings suggest that IgG from patients with SLE or APS is capable of stimulating vWF release and that this ability may be implicated in the thrombotic events that are observed in these conditions

KEY WORDS: von Willebrand factor antigen, Systemic lupus erythematosus, Anti-phospholipid syndrome, Endothelium, Immunoglobulin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 LupusHome page
P R J Ames, A Margarita, J D. Alves, C Tommasino, L Iannaccone, and V Brancaccio
Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies
Lupus, April 1, 2002; 11(4): 208 - 214.
[Abstract] [PDF]

Home page
 Clin. Chem.Home page
J. Nojima, H. Kuratsune, E. Suehisa, Y. Futsukaichi, H. Yamanishi, T. Machii, Y. Iwatani, and Y. Kanakura
Association between the Prevalence of Antibodies to {beta}2-Glycoprotein I, Prothrombin, Protein C, Protein S, and Annexin V in Patients with Systemic Lupus Erythematosus and Thrombotic and Thrombocytopenic Complications
Clin. Chem., June 1, 2001; 47(6): 1008 - 1015.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
D O'GRADAIGH, D G I SCOTT, and N LEVELL
Hug(h)e(s') ears: an unusual presentation of antiphospholipid syndrome
Ann Rheum Dis, January 1, 1999; 58(1): 65 - 66.
[Full Text]

Home page
 LupusHome page
M. D. Lockshin
Antiphospholipid Antibody: Future Developments
Lupus, August 1, 1994; 3(4): 309 - 311.
[Abstract] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.